News Search Results
Dec 05, 2025, 08:00 ET K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer
progress of gintemetostat (KTX-1001), a potent oral NSD2/MMSET inhibitor being developed for patients with t(4;14) multiple myeloma," said Saad Usmani, M.D., MBA, Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center. "In the dose-escalation phase, gintemetostat monotherapy showed a favorable
More news about: K36 Therapeutics
Dec 04, 2025, 06:00 ET AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-cell malignancies
expansion study and a Phase II pivotal trial.B-cell malignanciesB-cell malignancies — including non-Hodgkin lymphomas, multiple myeloma, and B-cell acute lymphoblastic leukemia (B-ALL) — account for the majority of blood cancers. Approximately 120,000 and 150,000 new cases are diagnosed
More news about: AvenCell Therapeutics, Inc.
Dec 03, 2025, 12:00 ET ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
de-risk clinical development. Supporting indications include acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. ImpriMed operates two laboratories: the Silicon Valley lab is A2LA-accredited to ISO 17025, and the Seoul lab is KGMP-certified and approved for IVD
More news about: ImpriMed
Dec 03, 2025, 10:20 ET OneOncology and OneR Partner Practice Investigators to Present Broad Portfolio of Data at the 2025 American Society of Hematology Annual Meeting
Key Highlights25 scientific abstracts spanning lymphoma, leukemia, and multiple myeloma underscore the essential role of community-based investigators in accelerating blood cancer research.• Data show bi-specific antibodies can be safely administered
More news about: OneOncology, LLC.
Dec 03, 2025, 10:00 ET Florida Cancer Specialists & Research Institute Contributing To Breakthroughs In Treatment of Blood Cancers & Disorders
plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 studyFunctional high-risk relapsed/refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysisA comprehensive list of abstracts presented
More news about: Florida Cancer Specialists & Research Institute
Dec 02, 2025, 14:00 ET Blood Cancer United, formerly The Leukemia & Lymphoma Society, Announces New Funding for Lifesaving Cancer Breakthroughs
M.D., who leads the Myeloma CAR-T/Immunotherapy program at Stanford Medicine in California, is funded under a Scholar in Clinical Research award reserved for highly qualified, early- to mid-career researchers. Dr. Sidana is looking at new treatment approaches for multiple myeloma in clinical trials and
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Dec 02, 2025, 08:15 ET AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
Session 654: Multiple Myeloma: Pharmacologic Therapies: Advances in Treatment Strategies for Relapsed/Refractory Multiple Myeloma1875
More news about: AbbVie Inc.
Dec 02, 2025, 08:00 ET Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition
discoveries from their basic science and clinical research programs to advance the understanding of blood cancers, such as lymphoma, leukemia and multiple myeloma, as well as classical hematology disorders at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6–9,
More news about: Rutgers Cancer Institute and RWJBarnabas Health
Dec 01, 2025, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Dec 01, 2025, 08:00 ET Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)December 7
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Dec 01, 2025, 07:00 ET Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Nov 27, 2025, 00:34 ET IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
Autoleucel) has been approved by the Hong Kong Department of Health. The therapy is indicated for adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received three or more prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent. This
More news about: IASO Bio
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
Initially the development of IVT-8086 is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer, multiple myeloma and pancreatic cancer. For further information visit our website at
More news about: Innova Therapeutics
Nov 25, 2025, 10:06 ET Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
Initially the development of IVT-8086 is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer, multiple myeloma and pancreatic cancer. For further information visit our website at
More news about: Innova Therapeutics
Nov 24, 2025, 10:27 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications,
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 10:20 ET Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications,
More news about: Menarini Industrie Farmaceutiche Riunite
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
refractory large B-cell lymphoma (ABSTRACT 25-7543)Multiple MyelomaReal-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium (ABSTRACT 25-2557) Phase 1 study
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 20, 2025, 13:16 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
of its reference product (Xgeva, developed by Amgen). JUBEREQ is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is
More news about: Accord BioPharma
Nov 19, 2025, 09:32 ET Canopy Study Selected for Oral Presentation at ASH 2025
Parrinello, C. M., & Ascha, M. S. (2024, December 9). Electronic patient-reported outcome (ePRO) symptom monitoring for relapsed/refractory multiple myeloma in community settings, focusing on bispecific antibody therapy. American Society of Hematology Annual Meeting
More news about: Canopy
Nov 18, 2025, 08:00 ET Berenson Cancer Center Announces Publication in Haematologica
2025 /PRNewswire/ -- Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal
More news about: Institute for Myeloma & Bone Cancer Research
Nov 18, 2025, 08:00 ET Kangpu to Present Latest Study Results of epaldeudomide (KPG-818) at the 67th ASH Annual Meeting
Study Poster Number: 5809 Poster Category: 654. Multiple Myeloma: Pharmacologic Therapies: Poster III Presenter: Dr. Aaron Rosenberg, MD, UC Davis Comprehensive Cancer
More news about: Kangpu Biopharmaceuticals
Nov 18, 2025, 07:00 ET BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained rights to develop motixafortide
More news about: BioLineRx Ltd.
Nov 17, 2025, 07:00 ET BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.
Nov 13, 2025, 07:00 ET Tract Bio Announces Opening of New Laboratory at The Pearl Innovation District
platform, stemECHO™, to transform treatment of highly-prevalent cancers and inflammatory diseases, including chronic myeloid leukemia (CML), multiple myeloma (MM), acute myeloid leukemia (AML), oesophageal adenocarcinoma, lung, pancreatic, ovarian and gastric cancer, as well as chronic obstructive pulmonary
More news about: Tract Bio